BioPlus launches application for physicians
ALTAMONTE SPRINGS, Fla. — A specialty pharmacy provider has launched an application that it said will reduce the administrative burden of reimbursement, writing prescriptions, monitoring adherence and reviewing drug lists.
BioPlus Specialty Pharmacy announced the launch of TAP App, short for Therapy Access Portal, designed to allow physicians to monitor patients from initial intake through benefit verification and shipping, and make data on adherence issues, medication possession ratios, adverse drug reactions and other issues more easily available.
"Our new TAP App for physicians is right in line with [the Agency for Healthcare Research and Quality’s] suggestion of leveraging technology to eliminate medication errors," BioPlus president and CEO Stephen Vogt said. "Aside from the obvious benefit to patients’ health, diminishing medical errors lowers costs, especially in light of a study earlier this year in the journal Health Affairs [that found] that the estimated total cost of measurable medical errors in the United States is $17.1 billion annually, with the most frequent medical injuries being adverse events associated with medications."
According to the AHRQ, between 28% and 95% of harmful side effects can be prevented by using computerized monitoring systems to reduce medication errors, while computerized ordering of medications potentially could prevent up to 84% of dose, frequency and route errors.
More than $2 billion added to workers’ compensation pharmacy costs, report finds
ST. LOUIS — Workers’ compensation pharmacy costs took on an extra $2.1 billion in 2011 due to unnecessary use of more expensive drugs, according to a new report by pharmacy benefit manager Express Scripts.
In its 2011 Express Scripts "Workers’ Compensation Drug Trend Report," the PBM found that use of higher-cost medications when therapeutically equivalent, lower-cost alternatives were available accounted for nearly all of the $2.1 billion in wasted pharmacy-related spending last year for payers that implement and optimize workers’ compensation pharmacy benefit management programs. About 125 million people are eligible for workers’ compensation benefits in the United States, and about 4.2 million suffer from a work-related injury or illness each year, according to ESI.
The drugs with the highest annual cost per user in 2011 were narcotic analgesics, which accounted for 38% of drug spending and 34% of utilization, and the top six therapy classes — which also included anticonvulsants, anti-inflammatory and dermatological medications — accounted for 76.2% of total drug spending.
ESI launches ScreenRx, offers preview of 2011 ‘Drug Trend Report’
ST. LOUIS — Fresh off the heels of its merger with Medco Health Solutions, pharmacy benefit manager Express Scripts announced Monday the launch of a medication nonadherence detection system and offered a preview of its annual "Drug Trend Report."
ScreenRx uses predictive modeling to detect future risk for nonadherence and tailors interventions for individual patients, offering them interventions to help them stay on their therapies once they’re identified. The program considers more than 400 known factors about the patient, physician, disease and therapy to identify who is most likely to stop taking their medications and identify ways to prevent nonadherence, such as daily alerts, 90-day fills or auto-renewals.
"ScreenRx enables Express Scripts to provide the most appropriate assistance to help each individual patient make healthier decisions, months after they might stop taking their medication," ESI chief medical officer Steve Miller said. "This solution brings the country one step closer to more affordable and effective care."
According to the 2011 "Drug Trend Report," for many therapies, less than 50% of patients take their medications as prescribed, costing the country’s healthcare system $317.4 billion in 2011, while eliminating nonadherence would cover the cost of providing health care for more than 44.8 million uninsured Americans.
The report also found that spending on prescription drugs increased 2.7% in 2011, the lowest annual drug trend the PBM has ever recorded. Trend for traditional medications fell to 0.1%, while specialty drug trend increased by 17.1%, with the top three specialty classes — inflammatory diseases, multiple sclerosis and cancer — accounting for 57.6% of total specialty spending. Meanwhile, hepatitis C had the highest cost increase of any specialty therapy class thanks to the introduction of new drugs.
Meanwhile, a 7% trend was found in diabetes, which accounts for the largest drug spend.